Emergent BioSolutions Inc. — Form 8-K Summary
Business context and reporting period
Filed November 4, 2026, to report an amendment to an existing U.S. government contract. This is an event filing, not a periodic financial report.
Key financial and operating details
- The contract modification exercises an option period under an existing indefinite-delivery/indefinite-quantity contract and is valued at up to $22.3 million.
- It covers supply of BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War for use by all branches of the U.S. military as pre-exposure prophylaxis against anthrax.
- The first delivery, valued at approximately $7.4 million, is expected to begin in 2026; remaining deliveries are expected in 2027.
- The filing provides no information on recognized revenue, profit, cash flow, margins, debt, liquidity, or the modification’s expected profitability.
Changes, outlook, and other considerations
The filing does not provide a comparable prior-period amount or describe other changes to the contract. Delivery timing is stated as expected, and the award is valued at “up to” $22.3 million. The filing says the modification’s description is qualified by the full text, which Emergent plans to file with its 2026 Form 10-K.
Important facts to verify
- The full modification terms and any conditions affecting the maximum contract value.
- Whether deliveries occur on the stated schedule and whether the expected amounts are ultimately recognized as revenue.
- Any later disclosures about costs, profitability, or changes to the delivery order.